The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
Open accessAbstract
BACKGROUND: Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity. METHODS: In all, 126 IBD patients and 32 irritable bowel syndrome (IBS) patients needing colonoscopy delivered a sample of feces prior to the start of bowel cleansing. Besides collection of symptom scores and blood tests, experienced endoscopists recorded the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Crohn's Disease Endoscopic Index of Severity (CDEIS) in Crohn's disease (CD) patients and the Mayo endoscopic score in ulcerative colitis (UC) patients. Stool samples were shipped for central calprotectin PhiCal Assay (enzyme-linked immunosorbent assay [ELISA]). Correlation analysis was done with Pearson statistics. RESULTS: The median (interquartile range [IQR]) fecal calprotectin levels were 175 (44-938) μg/g in CD, 465 (61-1128) μg/g in UC, and 54 (16-139) μg/g in IBS. Correlations were significant with endoscopic disease scores in both CD and in UC. Using ROC statistics, a cutoff value of 250 μg/g indicated the presence of large ulcers with a sensitivity of 60.4% and a specificity of 79.5% (positive predictive value [PPV] 78.4%, negative predictive value [NPV] 62.0%) in CD. Levels ≤ 250 μg/g predicted endoscopic remission (CDEIS ≤ 3) with 94.1% sensitivity and 62.2% specificity (PPV 48.5%, NPV 96.6%). In UC, a fecal calprotectin >250 μg/g gave a sensitivity of 71.0% and a specificity of 100.0% (PPV 100.0%, NPV 47.1%) for active mucosal disease activity (Mayo >0). Calprotectin levels significantly correlated with symptom scores in UC (r = 0.561, P < 0.001), but not in CD. CONCLUSIONS: Fecal calprotectin levels correlate significantly with endoscopic disease activity in IBD. The test appears useful in clinical practice for assessment of endoscopic activity and remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Self-citationSeverity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Self-citationMary, J. Y., & Modigliani, R. (1989) · Gut · doi:10.1136/gut.30.7.983 · Cited by 884
van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010) · BMJ · doi:10.1136/bmj.c3369 · Cited by 714
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., Present, D. H., Rutgeerts, P., Schölmerich, J., Stange, E. F., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31072 · Cited by 686
Self-citationAssessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study
RØseth, A. G., Fagerhol, M. K., Aadland, E., & Schjønsby, H. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011186 · Cited by 669
Schoepfer, A. M., Beglinger, C., Straumann, A., Trummler, M., Vavricka, S. R., Bruegger, L. E., & Seibold, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.545 · Cited by 570
Costa, F., Mumolo, M. G., Ceccarelli, L., Bellini, M., Romano, M. R., Sterpi, C., Ricchiuti, A., Marchi, S., & Bottai, M. (2005) · Gut · doi:10.1136/gut.2004.043406 · Cited by 550
A. G. Røseth, P. N. S. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529950172835 · Cited by 422
Biological Therapies for Inflammatory Bowel Diseases
Rutgeerts, P., Vermeire, S., & Van Assche, G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.001 · Cited by 363
Self-citationSchoepfer, A. M., Beglinger, C., Straumann, A., Trummler, M., Renzulli, P., & Seibold, F. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20986 · Cited by 326
High prevalence of NSAID enteropathy as shown by a simple faecal test
Tibble, J. A., Sigthorsson, G., Foster, R., Scott, D., Fagerhol, M. K., Roseth, A., & Bjarnason, I. (1999) · Gut · doi:10.1136/gut.45.3.362 · Cited by 307
Røseth, A. G., Aadland, E., & Grzyb, K. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410007971 · Cited by 267
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
D'Haens, G., Geboes, K., Ponette, E., Penninckx, F., & Rutgeerts, P. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70027-1 · Cited by 246
Self-citationBunn, S. K., Bisset, W. M., Main, M. J. C., Gray, E. S., Olson, S., & Golden, B. E. (2001) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2001.tb07395.x · Cited by 237
Sipponen, T., Savilahti, E., Kärkkäinen, P., Kolho, K.-L., Nuutinen, H., Turunen, U., & Färkkilä, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20490 · Cited by 236
Carroccio, A., Iacono, G., Cottone, M., Di Prima, L., Cartabellotta, F., Cavataio, F., Scalici, C., Montalto, G., Di Fede, G., Rini, G., et al. (2003) · Clinical Chemistry · doi:10.1373/49.6.861 · Cited by 221
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease
D’Incà, R., Dal Pont, E., Di Leo, V., Ferronato, A., Fries, W., Vettorato, M. G., Martines, D., & Sturniolo, G. C. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0159-9 · Cited by 215
Limburg, P. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01987-0 · Cited by 171
Sipponen, T. M., af Björkesten, C.-G., Färkkilä, M. A., Nuutinen, H. U., Savilahti, E., & Kolho, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365520903483650 · Cited by 155
Meucci, G., Fasoli, R. A., Saibeni, S., Valpiani, D., Gullotta, R., Colombo, E., Renata D'Incà, Terpin, M., & Lombardi, G. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21838 · Cited by 119
D’Haens, G., Fedorak, R. N., Lémann, M., Feagan, B. G., Kamm, M. A., Cosnes, J., Rutgeerts, P. J., Marteau, P. R., Travis, S. P. L., Schölmerich, J., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21034 · Cited by 101
Self-citationA fat chance for hepatocyte transplantation?
Thomas, J. A., & Forbes, S. J. (2009) · Gut · doi:10.1136/gut.2008.171314 · Cited by 9
Cited by
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationKobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Self-citationColombel, J.-F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vaňásek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hébuterne, X., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32641-7 · Cited by 921
Self-citationEuropean evidence based consensus for endoscopy in inflammatory bowel disease
Annese, V., Daperno, M., Rutter, M. D., Amiot, A., Bossuyt, P., East, J., Ferrante, M., Götz, M., Katsanos, K. H., Kießlich, R., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.09.016 · Cited by 815
Self-citationMosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
Metadata
- Authors
- DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., Van Olmen, G., & Rutgeerts, P.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12
- Volume
- 18
- Issue
- 12
- Pages
- 2218-2224
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2159561736
- Cited by
- 816
- References
- 31
- FWCI
- 30.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.